MedTrace Logo

Study on the Mechanism of lcn2 in Obesity

NCT04573998 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-10-05

No results posted yet for this study

Summary

Obesity is now becoming a worldwide serious problem. Obesity is associated with a spectrum of severe diseases, including diabetes, cardiovascular diseases, and cancers. Lipocalin 2 (LCN2), also known as neutrophil gelatinase associated lipocalin (NGAL), is a member of the lipocalin family. Due to its upregulated expression in infection, LCN2 is originally considered to be a key regulator of immune response. Subsequent investigations revealed that LCN2 is expressed in many tissues and is related to a variety of diseases, including obesity. LCN2 was reported to be increased in obesity individuals. Thus, the investigators decide to investigate the relationship between LCN2 and obesity.

Conditions

  • Obesity; Endocrine

Interventions

PROCEDURE

LSG

bariatric surgery

Sponsors & Collaborators

  • Shen Qu

    lead OTHER

Principal Investigators

  • Shen Qu, Dr. · Shanghai 10th People's Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2024-03-01
Completion
2024-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573998 on ClinicalTrials.gov